Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8561317 | 1.00 | GAA (1.00) | GAANPY5RAOC3KDM4EALDH1A1 | |
| SCHEMBL8285851 | 1.00 | GAA (1.00) | GAANPY5RAOC3KDM4EALDH1A1 | |
| Water SCHEMBL3312040 | 0.98 | GAA (0.97) | GAANPY5RAOC3KDM4EALDH1A1 | |
| Water SCHEMBL864746 | 0.98 | GAA (0.97) | GAANPY5RAOC3KDM4EALDH1A1 | |
| Water SCHEMBL3312041 | 0.98 | GAA (0.97) | GAANPY5RAOC3KDM4EALDH1A1 | |
| Water SCHEMBL864745 | 0.98 | GAA (0.97) | GAANPY5RAOC3KDM4EALDH1A1 | |
| Water SCHEMBL7871774 | 0.98 | GAA (0.97) | GAANPY5RAOC3KDM4EALDH1A1 | |
| SCHEMBL25409408 | 0.89 | GAA (0.80) | GAANPY5RAOC3KDM4EALDH1A1 | |
| SCHEMBL4992458 | 0.89 | GAA (0.80) | GAANPY5RAOC3KDM4EALDH1A1 | |
| SCHEMBL5804993 | 0.89 | GAA (0.80) | GAANPY5RAOC3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| EP-2988597-B1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | HARVARD COLLEGE (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON S.P.A. (IT) | 2021-08-12 | — | — | US | disclosed |
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| US-10913764-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-9982005-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9872911-B2 | Alpha-aminoamidine polymers and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872911-B2 | Alpha-aminoamidine polymers and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | SCHERING CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-7256177-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256177-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-7253160-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GAA 3533/4885NPY5R 3588/4885AOC3 2427/4885 |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | MGAM, BPGM, MRPL21 | GAA 326/4885NPY5R 4422/4885AOC3 4038/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | GAA 3533/4885NPY5R 3588/4885AOC3 2427/4885 |
| US-10913764-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | GAA 669/4885NPY5R 4375/4885AOC3 2200/4885 |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | LIFR, FLT3, F12 | GAA 2413/4885NPY5R 3671/4885AOC3 714/4885 |
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | DPP3, DPP7, DPP4 | GAA 160/4885NPY5R 4204/4885AOC3 2963/4885 |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | GAA 3533/4885NPY5R 3588/4885AOC3 2427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.